EUVIMEDEUVIMED entdecken
Crossref

Abstract 16082: SGLT2 Inhibitors and Major Adverse Cardiovascular Events in Chemotherapy-Related Cardiomyopathy: A Real-World Comparative Effectiveness Study

Keshav Garg, Ankit Agrawal, Haritha Gandicheruvu, Nitesh Gautam, Vidhi Bhanushali, Subhi J Al'Aref

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.16082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Keshav Garg und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cancer therapy-related cardiac dysfunction (CTRCD) with HFrEF is a serious complication of cardiotoxic cancer therapies, and data on the effectiveness of SGLT2 inhibitors in this population are limited. We aimed to evaluate the association between SGLT2 inhibitor use and major adverse cardiovascular events (MACE) in patients with CTRCD and HFrEF using real-world data. Hypothesis: SGLT2i use is associated with reduced MACE and all-cause mortality in patients with cancer therapy-related HFrEF compared with non-users.

Methods

Using the TriNetX U.S. Collaborative Network, we identified adults aged ≥18 with exposure to cardiotoxic antineoplastic agents (anthracyclines, trastuzumab, cyclophosphamide, bevacizumab, cisplatin, paclitaxel, sunitinib, sorafenib, fluorouracil, epirubicin, methotrexate) and subsequent systolic heart failure. Patients were stratified by GDMT regimen with versus without SGLT2i (empagliflozin or dapagliflozin) initiated after HFrEF diagnosis. Propensity score matching (1:1) balanced age, sex, race, hypertension, diabetes, obesity, tobacco use, dyslipidemia, chronic ischemic heart disease, and chronic kidney disease. The primary outcome was MACE (composite of cerebral infarction, acute myocardial infarction (AMI), and all-cause mortality). Individual components were assessed as secondary outcomes. Outcomes were evaluated at 1- and 5-year and Forest plots were generated.

Results

After matching, 1,693 patients were included per cohort with well-balanced baseline characteristics (Figure 1). At 1 year, SGLT2i-based GDMT was associated with significantly lower MACE (hazard ratio (HR) 0.57; 95% confidence interval (CI) 0.48-0.67; p

Zitieren

APA

Garg, K., Agrawal, A., Gandicheruvu, H., Gautam, N., Bhanushali, V., & Al'Aref, S. J. (2026). Abstract 16082: SGLT2 Inhibitors and Major Adverse Cardiovascular Events in Chemotherapy-Related Cardiomyopathy: A Real-World Comparative Effectiveness Study. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.16082

Vancouver

Garg K, Agrawal A, Gandicheruvu H, Gautam N, Bhanushali V, Al'Aref SJ. Abstract 16082: SGLT2 Inhibitors and Major Adverse Cardiovascular Events in Chemotherapy-Related Cardiomyopathy: A Real-World Comparative Effectiveness Study. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.16082

BibTeX
@article{Garg2026,
  author = {Garg, Keshav and Agrawal, Ankit and Gandicheruvu, Haritha and Gautam, Nitesh and Bhanushali, Vidhi and Al'Aref, Subhi J},
  title = {Abstract 16082: SGLT2 Inhibitors and Major Adverse Cardiovascular Events in Chemotherapy-Related Cardiomyopathy: A Real-World Comparative Effectiveness Study},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.16082}
}
Kostenlos starten →